2020 Feb 11;41:102009. doi: 10.1016/j.msard.2020.102009.Author information
Abstract
BACKGROUND:
Growing evidence supports that cannabinoids relieve MS-related spasticity but little is known about cannabis use among people with MS (PwMS) and spasticity.
OBJECTIVE:
To characterize cannabis use among PwMS and spasticity.
METHODS:
As part of baseline data collection for a spasticity intervention trial in Oregon, PwMS and self-reported spasticity answered questions about cannabis use.
RESULTS:
54% reported ever using cannabis and 36% currently use. 79% use multiple routes of administration, 58% use at least daily. 79% find cannabis helpful for spasticity and 26% use cannabis and prescribed oral antispasticity medications.
CONCLUSIONS:
Many PwMS and spasticity use cannabis and report it helps their spasticity.
Published by Elsevier B.V.
KEYWORDS: Cannabinoids, Cannabis, Multiple sclerosis, Spasticity
- PMID: 32086163
- DOI: 10.1016/j.msard.2020.102009
Conflict of interest statement
Declaration of Competing Interest Dr. Rice has done consulting for Greenwich Biosciences. Ms. Hugos declares that there is no conflict of interest. Ms. Hildebrand declares that there is no conflict of interest. Dr. Cameron has done consulting for Adamas Pharmaceuticals Inc. and for Greenwich Biosciences.
